<PAGE> 1
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
[x] Annual report under Section 13 or 15(d) of the Securities Exchange Act of
1934
For the fiscal year ended June 30, 1996
[ ] Transition report under Section 13 or 15(d)of the Securities Exchange Act
of 1934
For the transition period from____________to____________
Commission file number 0-26972
SWISSRAY International, Inc.
(Name of Small Business Issuer in Its Charter)
New York 16-0950197
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
747 Third Avenue, New York, New York 10017
(Address of Principal Executive Office) (Zip Code)
New York - 212-644-6497 Switzerland - 011 41 41 919 90 50
(Issuer's Telephone Number, Including Area Code)
Securities registered under Section 12(b) of the Exchange Act: None
Securities registered under Section 12(g) of the Exchange Act:
Common Stock, par value $.01 per share
(Title of Class)
Check whether the issuer; (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for past 90 days. Yes xx No
--- ---
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]
1
<PAGE> 2
State issuer's revenues for its most recent fiscal year - $10,899,222
The number of shares outstanding of each of the Registrant's classes of
Common Stock, as of October 2, 1996 is 13,751,142 shares, all of one class of
$.01 par value Common Stock. Of this number a total of 9,981,142 shares having
an aggregate market value of $39,924,568, based on the closing price of the
Registrant's common stock of $4.00 on October 2, 1996 as quoted on the NASDAQ
SmallCap market, were held by non-affiliates * of the Registrant.
* Affiliates for the purpose of this item refers to the Registrant's
officers and directors and/or any persons or firms (excluding those
brokerage firms and/or clearing houses and/or depository companies holding
Registrant's securities as record holders only for their respective
clienteles' beneficial interest) owning 5% or more of the Registrant's
Common Stock, both of record and beneficially - all as of October 2, 1996.
ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PAST FIVE YEARS
Check whether the issuer has filed all documents and reports required to
be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution
of securities under a plan confirmed by a court. Yes No
--- ---
Not Applicable
APPLICABLE ONLY TO CORPORATE REGISTRANTS
State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date. 13,751,142 shares as of
October 2, 1996.
Transitional Small Business Disclosure Format: Yes No
--- ---
DOCUMENTS INCORPORATED BY REFERENCE
If the following documents are incorporated by reference, briefly describe
them and identify the part of the Form 10-KSB (e.g., Part I, Part II, etc.)into
which the document is incorporated: (1) any annual report to security-holders;
(2) any proxy or information statement; and (3) any prospectus filed pursuant to
Rule 424(b) or (c) of the Securities Act of 1933 ("Securities Act").
None
2
<PAGE> 3
TABLE OF CONTENTS
Page
Number
PART I
Item 1. Description of Business 4
Item 2. Description of Property 16
Item 3. Legal Proceedings 16
Item 4. Submission of Matters to a Vote of
Security Holders 17
PART II
Item 5. Market For Common Equity and Related
Stockholder Matters 17
Item 6. Management's Discussion and Analysis
or Plan of Operation 18
Item 7. Financial Statements 23
F1 - F15
Item 8. Changes in and Disagreements With
Accountants on Accounting and
Financial Disclosure 24
PART III
Item 9. Directors, Executive Officers, Promoters
and Control Persons; Compliance With
Section 16(a) of the Exchange Act 24
Item 10. Executive Compensation 26
Item 11. Security Ownership of Certain Beneficial
Owners and Management 27
Item 12. Certain Relationships and Related
Transactions 28
Item 13. Exhibits, List and Reports on Form 8-K 28
3
<PAGE> 4
PART I
ITEM 1. DESCRIPTION OF BUSINESS
Background Summary
The Company was incorporated under the laws of the State of New York on
January 2, 1968 under the name CGS Units Incorporated. On May 23, 1994, the
Company acquired 100% of the outstanding securities of Direct Marketing
Services, Inc., a company incorporated in the State of Delaware on June 3, 1993.
On June 6, 1994, the Company merged with Direct Marketing Services, Inc. and the
surviving entity changed its name to DMS Industries, Inc. In accordance with the
terms and conditions of an Asset and Stock Purchase Agreement in May of 1995 the
Company discontinued the operations then being conducted by DMS Industries, Inc.
and shortly thereafter entered into an Acquisition Agreement with SR-Medical AG
(a Swiss corporation) and others whereby it acquired all of the outstanding
securities of SR-Medical AG. The current Company operations as described herein
are being conducted principally through the Company's wholly owned subsidiary,
SR-Medical AG, and the latter's wholly owned subsidiaries, Teleray AG (a Swiss
corporation) and SR-Medical GmbH (a German corporation) as well as through the
Company's newly formed (in December 1995) wholly owned subsidiary, SR Finance AG
(a Swiss corporation). Unless otherwise specifically indicated all references
hereinafter to the Company and/or Registrant refer to the Registrant and its
subsidiaries. See also "Company Organizational Chart" appearing hereinafter.
While the Registrant currently maintains an executive office in the United
States at 747 Third Avenue, New York, New York 10017, its principal executive
and operating offices, showroom and demonstration facilities are all located in
Switzerland at Industriestrasse 6, 6285 Hitzkirch, Switzerland and its telephone
number is (011) 41 41 919 90 50. See Item 2 "Description of Property".
The Company, operating through its subsidiaries, is engaged in the
diagnostic X-ray medical equipment market, wherein it develops, assembles and
sells worldwide, both directly and indirectly under its label SWISSRAY as well
as to Official Equipment Manufacturers (OEM) partners, X-ray units and
accessories. It has recently developed a new digital imaging processing system
called "SwissVision" designed to enhance X-ray diagnosis with computer
assistance specifically by integrating computer technology with radiology in
order to support the radiologist in diagnostic functions utilizing a Digital,
recent developed, Add-on Bucky which allows for direct digitalization of the
radiology process (and eliminates the need for the use and subsequent storage
and/or retrieval of X-ray film).
The Company
SR-Medical AG, a wholly owned subsidiary of the Company, (formed under the
laws of Switzerland in 1988) develops, assembles and markets worldwide, directly
and/or indirectly, under its SWISSRAY label as well as to OEM partners,
diagnostic X-ray medical equipment, components, units and accessories. Its
products are designed to encompass state of the art technology with competitive
price - performance ratios for sale through its existing distribution network
(and eventual proposed sale into expanded geographical markets).
4
<PAGE> 5
Telray AG, a wholly owned subsidiary of SR-Medical AG, (formed under the
laws of Switzerland in 1984) was established so as to integrate computer
technology with radiology and has recently developed new digital imaging systems
("SwissVision") designed to (a) enhance X-ray diagnosis with computer
assistance, (b) support radiologists' diagnosis through certain graphical
functions and (c) integrate related managerial tasks into a general office
automation environment. Initial SwissVision installations were accomplished in
late 1993 with the newly developed Digital Add-on Bucky allowing for direct
digitalization (and elimination of X-ray film) being developed shortly
thereafter.
The Digital Add-on Bucky and SwissVision (or X-Vision in Germany) together
constitute one direct digital radiology system and, accordingly, may be sold as
one package at prices approximating $200,000 to $250,000 for the complete
digital imaging system dependent upon peripherals ordered. SwissVision is also
available as a software module called X-Vision that integrates direct digital
radiology to MediStar, a German market leader for computer systems in medical
practices. The Company is systematically acquiring interface specifications and
device drivers from other input and output peripheral manufacturers in the field
of direct digital radiology (e.g. laser scanners). By integrating this
proprietary know how management intends to increase the number of possible
applications of SwissVision although no assurance can be given that such
intentions will bear fruition.
The Company's OEM agreement (entered into in the fall of 1992) is with a
major multinational X-ray equipment manufacturer (Phillips GmbH, Hamburg) and
was initially intended for purposes of marketing a MRS
(Multi-Radiography-System) unit, developed and produced exclusively for the OEM
partner (who has since marketed MRS units worldwide with initial major shipments
to the OEM partner having commenced in 1994).
In July of 1996 the Company announced that it had signed a multimillion
dollar contract with Phillips Medical Systems ("PMS") for the production and
delivery of conventional X-ray equipment over a four and one-half year period
commencing June of 1996. Under the terms of the original equipment manufacturing
contract ("OEM"), the Company is obligated to design, manufacture and deliver
its products to be marketed by PMS on a worldwide basis under its own name. Such
X-ray equipment intended to meet both European Common Market and United States
FDA standards. Sales support and maintenance are to be provided by PMS. Initial
product shipments, valued in excess of $8,000,000, are expected to be delivered
within the next twelve months. Management of the Company believes that it having
been chosen as an important supplier to a multi-national concern for X-ray
equipment is a significant accomplishment in the Company's overall progress and
should have a positive effect upon its revenues and earnings for the next
several years.
Most recently, in September 1996, the Hamburg based radiography division
of PMS expanded the agreement entered into in July 1996 (referred to above) so
as to further develop conventional X-ray system components for certain fields of
radiography, with the Company to handle all aspects relating to manufacturing
and with PMS marketing the systems worldwide on an exclusive basis. Management
of the Company expects that the aforesaid expansion of its existing agreement
with PMS should result in a substantial increase in both Company exposure
5
<PAGE> 6
and sales.
The MRS unit may be considered to be traditional X-ray equipment where
impressions are made on film. Components to such MRS (basic) system include
X-ray tables and standard X-ray generators with control panels as well as X-ray
tubes and cables. The MRS is currently marketed as a Company corporate product
(under the name of the Company's OEM partner or under the Company's name if
delivered to someone other than its OEM partner) over a marketing network of in
excess of approximately 80 affiliates worldwide. The MRS unit has received World
Health Organization of the United Nations (WHO) approval (as hereinafter
indicated) and is listed by the WHO as a reference product whose specifications
must be met by other competing products.
The following organizational chart is designed as an overview - summary of
both the Company's structure and division of corporate responsibilities between
certain designated business areas, to wit: Radiology and Digital Imaging
Systems.
6
<PAGE> 7
COMPANY ORGANIZATIONAL CHART
SWISSRAY International, Inc.
Registrant
(formally DMS Industries, Inc.)
SR-Medical AG Wholly Owned SR Finance AG
[1] Subsidiaries [3]
(A Swiss Corporation) (A Swiss Corporation)
Teleray AG SR-Medical GmbH Wholly Owned
[2] Subsidiaries of
(A Swiss Corporation) (A German Corporation) SR Medical AG
OPERATIONAL STRUCTURE OF THE SWISSRAY GROUP
SWISSRAY GROUP
[1] X-ray Units and Components Digital Imaging Systems [2]
- R&D; Technical Services - R&D; Technical Services
- Operation - Software Development
- Finance & Administration - Marketing & Sales
- Marketing & Sales
- Affiliates
- Dealer Markets
- Export Markets
- OEM Markets
[3] SR Finance AG, organized in December 1995, to act as a service oriented
company exclusively servicing the other companies within the Company's
consolidated group in the areas of consultation, bookkeeping, logistics
and employment services.
Product Overview
In general, an X-ray unit consists of three components:
Component Function
X-Ray Stand Carries the X-ray tube on one
side and the X-ray sensitive
plate (or other reception
devices) on the other side
X-Ray Generator Power supply for the tube and control
circuitry with user interface
X-Ray Table Patient handling
7
<PAGE> 8
X-ray units have been used for over 100 years by doctors, radiologists,
hospitals and radiology centers as one of the basic multipurpose diagnostic
tools. Although the basic physical principles behind this examination instrument
are still principally the same, several components of such a unit have changed
in terms of power, quality, economy and control functions and may be considered
to be "high-tech" products.
The Company designs the components of its products in an effort to achieve
a consistent product philosophy in terms of quality, modularity and flexibility
towards special customer needs.
The Company products belong technologically to the newest generation of
X-ray units and are listed with relevant national and international health care
institutions and comply with their respective specifications or standards. The
MRS (heretofore referred to as having received WHO-approval) has comparative
advantages primarily in ergonomic features relating to its stand and table
designs (and related auxiliary equipment) as well as in user interface of the
generator controls. It also features a high degree of compatibility to
components which can be used on non-Company units as well. As heretofore
indicated the MRS unit is considered to be the traditional basic X-ray unit
utilizing film (and accordingly differs from the Company's more advanced digital
imaging system referred to herein as Digital Add-on Bucky and SwissVision which
doesn't utilize film but instead relies upon computer digitalization and
imaging).
Key proprietary know-how lies in the electronics of the
computer-controlled man machine interface allowing X-ray assistants (or
radiologists) to produce optimal exposures. Its database incorporates radiology
know-how in the form of optimal exposition parameters and programs which result
in preprogrammed quality (minimization of radiation dosage) and economy
(elimination of faulty exposures). The software-driven logic circuitry in
addition to controlling the power electronics during normal operation also
informs service engineers of malfunctions and enables them to perform functional
checks, readjustments and calibrations.
The following chart is intended to present a summarized overview of the
Company's most recent product developments (i.e., SwissVision and Digital Add-on
Bucky) as well as its earlier basic standard products (i.e. MRS units and
generators).
8
<PAGE> 9
Products Short Description/Features
MRS Multipurpose-Radiography System
for growth markets in developing
countries (OEM business) (1)
Generators High Frequency Technology;
Battery powered generators for installation
with several daily power cuts (intended for
developing countries)
SwissVision Digital imaging system compatible
with modern X-ray units (2)
Digital Add-on Direct Digitalization of Exposure (2)
Bucky
(1) Traditional basic X-ray equipment where pictures are made utilizing film.
Components to an MRS or basic system include X-ray tables and stands,
X-ray generators and control panels as well as X-ray tubes and cables.
(2) The digital imaging system consists of devices which optically receive the
X-ray and transform it into a digital picture made visible on a high speed
computer screen. The computer utilizes SwissVision software in order to
enable it to display, store, compare and transmit (via modem) these X-ray
pictures. The digital imaging system utilizes the basic components
described in footnote 1 above in addition to the aforesaid Add-on Bucky,
high speed computer and SwissVision software.
The Company presently has no domestic (U.S.) sales and derives all of its
revenues from its subsidiaries located in Switzerland and Germany. While the
Company intends to undertake marketing efforts in the U.S. (either by
introducing direct distribution and/or by joint venture with U.S. distributors,
manufacturers and/or medical industry related organizations) there can be no
assurance whatsoever that such plans will meet with any degree of success. The
Company's proposed entry into the U.S. market is expected to meet intense
competition since the Company's operations, while relatively well established
overseas, would nevertheless be new to the U.S. and there are inherent
difficulties whenever a company seeks to enter an established field or
pre-existing market. Accordingly, the Company expects to encounter intense
competition from any number of domestic (U.S.) firms which are substantially
larger, have more substantive histories, experience and records of successful
operations, greater financial, promotion, marketing (including distribution
networks) and other resources, more employees and a more diverse and extensive
line of products than the Company now has or may expect to have within the
reasonably foreseeable future. In addition to the competitive factors indicated
herein, the Company, operating through its Swiss and German subsidiaries, may be
subject to certain negative economic factors which affect foreign company's
seeking to enter U.S. markets. Such
9
<PAGE> 10
factors can include changes in exchange rates, political environment regarding
importation of competitive products and corresponding import restrictions,
tariffs or other U.S. government imposed protective measures for domestic
companies. See also Item 1 "Competition" hereinafter.
Research and Development/Digitalization
The Company has recently concentrated its research and development
activities in the area of Digital X-ray Imaging Systems and in that regard has
developed (a) SwissVision, a digital image processing system compatible with
modern X-ray units and (b) Digital Add-on Bucky, an input device allowing for
direct digitalization of X-ray images on the standard bucky table. These
products are currently ready for delivery and are expected to be installed
during the fourth quarter of 1996.
Management believes that the principal advantages relating to the use of
digital technologies within the field of radiology may be summarized as follows:
- Reduction of the radiation dosage per X-ray shot
- Availability of additional information per X-ray shot
- Reduction of handling time and cost (including storage and
transportation cost)
- Support of the trend towards specialization in medicine
Instead of exposing an X-ray sensitive film to radiation and then
chemically developing and fixing the captured exposure as an X-ray photograph,
X-ray sensitive plates are increasingly being used in order to receive and store
the captured radiation, which is then scanned and converted into digital
signals. The digital X-ray reception systems are more sensitive than X-ray films
and as a consequence the exposure of the patient to the radiation can be reduced
by up to 70%. By processing the digitized raw data on a computer, additional
information can be produced that supports diagnosis to a large extent. Since the
raw data stays available, different views or magnifications can be displayed on
a screen at all times with varying degrees of intensity so as to highlight
specific areas. Additionally, important savings may be realized in handling,
transport and storage. The chemical processing of film is dramatically reduced
or can be even totally substituted and the handling of chemicals and their
recycling becomes obsolete. The digital processing of an X-ray shot is
substantially faster than the conventional chemical procedures and cost and time
savings are encountered through in-house administrative handling of the X-ray
pictures. Another important feature of the digital radiology is the ability to
transmit the once digitized information via a modem to a specialist for a second
opinion or for in depth diagnosis. Accordingly, management believes that
digitalization supports the increasing general trend towards specialization in
medicine and intends to concentrate its efforts upon digitalization and software
peripherals associated therewith.
The following information summarizes certain features and related
information regarding the Company's aforesaid most recent and advanced products,
to wit: SwissVision and Digital Add-on Bucky.
10
<PAGE> 11
SwissVision
SwissVision allows import of scanned and digitized X-ray signals on
a standard PC workstation (DOS, Windows) via a standard interface and
display of the X-ray picture on a screen for immediate examination.
Special functions allow for computer assisted diagnosis. The standard
office automation PC functions (data editing, administration and archiving
as well as network and file transfer functions) are supported and/or
enhanced. SwissVision enables not only extended diagnostic features but
substantial time and cost savings in the X-ray process itself and in the
context of office automation and telecommunication and is compatible with
modern X-ray units and office systems utilizing standard interfaces.
The initial installation of SwissVision was accomplished in 1993 and
management believes (based upon user response) that such innovation has
the potential for substantial success within this technological area
although no assurance with respect thereto can be given especially in view
of the limited track record within this new area). SwissVision has won the
Innovation Award of the Swiss Chamber of Commerce (Central District).
Digital Add-on Bucky
With the Digital Add-on Bucky, in essence a compact X-ray
registering device (similar to digital photography) direct digitalization
is now feasible. The Digital Add-on Bucky may be considered a innovative
advance in the field of radiology and its design allows it to be mounted
on virtually every X-ray unit (instead of the conventional film bucky) so
as to establish a state-of-the-art radiology center.
The cost and time saving effects as a result of the combined use of
Digital Add-on Bucky and SwissVision are believed to be substantially due to the
facts that manual handling is put to a minimum and processing speed is at a
maximum, with an enhanced X-ray picture being displayed on a PC screen
approximately six seconds after the shot.
As a result of research and development already conducted the Company's
new products referred to herein, i.e. its Digital Add-on Bucky and SwissVision
(including software) is now considered to be fully developed. Nevertheless,
technology has in the past and continues to advance and in order to stay
"current" any company engaged in technological areas must continue to engage in
research and development activities. In that regard, the Company has expended
approximately $1,700,000 during fiscal year ended June 30, 1996 on research and
development, which sum represents approximately 16% of net sales volume and
further accounts for approximately 20% of all operating expenses for fiscal year
ended June 30, 1996.
The Digital Add-on Bucky was presented to the public in November 1994 at
MEDICA, Dusseldorf and in March 1995 at ECR's, Vienna; major trade shows for
medical systems. Additionally, the Company's digitalized computer oriented
products (i.e. its Add-on Bucky and SwissVision) were presented in Chicago,
Illinois at the Radiological Society of North America
11
<PAGE> 12
("RSNA") industry trade show in November 1995 and a further demonstration of all
its products was made in New York City in December 1995. The Company plans to
attend such additional industry trade shows as management deems advisable and in
that respect expects to attend the RSNA show in Chicago, Illinois in November
1996 (partially due to the extremely satisfactory response received as a result
of having demonstrated its products at RSNA in November 1995).
Plant, Equipment, Production and Operation
The Company does not manufacture or produce any components for its X-ray
units, but rather assembles purchased standard components and subassemblies
which are all built to its specifications. The assembled units are then tested,
calibrated, packed and shipped.
The Company's property and equipment as a percentage of total assets is
approximately 6%. With the exception of the MRS units every order runs through
the operation as a separate entity. There is virtually no stock of finished
products which remains on Company premises for any extended period of time since
assembly of components into finished products is upon Company customers request
and generally accomplished within a three month time frame. The Company stocks
such components as it deems necessary (with no shortage being anticipated; see
below) and its percentage of "finished products" at June 30, 1996 approximated
7% of inventory while raw materials, parts and supplies accounted for
approximately 64% of inventory with the balance of inventory (approximately 29%)
being work in process. MRS units are increasingly ordered in lots of up to 30
units which allows a more structured assembly approach. Average delivery time is
approximately three - four months.
A significant part of the Company's production capacity has been allocated
in the past to product development and product output can be raised through
reallocation of labor (from research and development to production) or if
necessary through addition of skilled personnel (readily available). There are
no substantial safety or environmental hazards involved with the assembling and
testing of X-ray units other than normal production related risks and the
Company has the necessary permits to run its operations in their present (or in
the foreseeable future) form.
Components, if not in stock, can be timely ordered upon Company receipt of
customer's order. The most important purchased components are X-ray tubes, power
supplies, transformers, electronic circuitry, tables and stands. In general, the
Company has several suppliers from whom to purchase key components and has
entered into certain exclusive supply agreements with certain suppliers located
in Switzerland (as well as USA and certain European countries). There is no
anticipated shortage in the supply of key components and/or delivery to Company
in a timely manner and/or in meeting Company delivery schedules in order to meet
Company requirements.
As heretofore indicated the Company does not manufacture components but
rather purchases same and thereafter utilizes its production capacity for
assembly and testing purposes. Accordingly, when, as and if necessary additional
technical service employees (on either a full
12
<PAGE> 13
time or per diem basis) may be employed by the Company and management does not
expect to encounter any significant difficulties with respect to hiring such
additional employees as are needed and has not, in the past, encountered any
significant difficulties in this production employee area. Current capacity for
production of MRS units is estimated between 450 to 600 units per year, while a
similar production capacity exists for the Company's Add-on Bucky. Management of
the Company does not envision any significant difficulties in increasing such
production levels if and when orders therefore are received over periods of
time.
Market Overview
The Company is designed to serve, with its basic and general radiology
units and systems, both the growth and the replacement X-ray markets with
Teleray's digital imaging systems being designed for and targeted at the
upgraded market through enlarging the scope of historical radiology by
integrating digital technology through utilization of the Company's SwissVision
and Digital Add-on Bucky products.
Relevant replacement and upgrading markets for the Company are primarily
within Switzerland and Germany, certain other industrialized countries and
Eastern Europe. Within these territories the underlying need is to replace
broken or inefficient components rather than investing in new units as well as
to upgrade the functional scope of installed X-ray units in order to comply with
increasing and/or changing or more stringent regulations with respect to
radiation dosage and other safety and/or potential environmental hazards (as
well as to increase efficiency through cost reduction and/or output increases).
End user categories of Company X-ray units and components are primarily
physicians and radiologists (approximately 3,500 within Switzerland), small and
medium size hospitals and radiology centers (approximately 27 within
Switzerland) as well as approximately 70 resale-dealers worldwide.
The Company has a geographically large sales network with revenue from
export activities (outside Switzerland) accounting for approximately 82% of
Company revenues during fiscal year ended June 30, 1996. For the fiscal year
ended June 30, 1996 sales to the Company's three largest customers accounting
for approximately 41% of all revenues while sales to the Company's single
largest customer during such period accounted for approximately 15% of all
revenues. Management considers its relationship with its largest customer(s) to
be satisfactory and the Company enjoys satisfactory working relationships with
the balance of its clientele. The loss of one or more of the Company's current
three largest customers or reduction of their purchasing from the Company (while
not anticipated) would have an adverse effect upon Company sales and the
corresponding financial condition of the Company until such time, if ever, as
new significant customers and production orders are received (to replace those
lost). Historically, no significant problems regarding retention of customers
has existed despite the fact that the amount of purchasing between the Company's
largest customers, has, in the past, varied. See also note 24 to the Company's
consolidated financial statements as regards additional information with respect
to both the Company's three largest customers and single largest customer for
certain indicated
13
<PAGE> 14
periods of time prior to its most recent fiscal year ended June 30, 1996.
Pricing and Services
The Company's present policy is to offer its products at rates comparable
to, if not lower than, those offered by its competitors. The Company also offers
custom orientation in all stages of a client relationship including
demonstrations, pre-sales customer services and consulting as well as end user
training, technical support and maintenance services inclusive of standard
guaranty and warranty terms.
Since Company products comply with all relevant standards and are listed
with all important health care organizations and institutions (e.g., WHO
approval for the MRS unit), the Company is able to bid on major national or
international governmental or institutional tenders and is not restricted to
tenders in developing countries only.
As heretofore indicated, the principal differences between standard MRS
units and the Company's Digital Add-on Bucky and SwissVision involve the fact
that MRS units continue to utilize traditional X-ray methods utilizing film
while the Add-on Bucky and SwissVision involve digitalization and computer
technology and eliminate film usage. See also "Research and Development"
regarding a more expanded discussion and differentiation between standard
traditional X-ray units (MRS) and the Company's newly developed Add-on Bucky and
SwissVision products. A complete digital imaging system costs in excess of
$200,000 while purchase of remote control tables and generators costs
approximately $60,000 and $35,000 respectively.
Competition
The health care imaging market is highly competitive. The Company's
principal competitors are multinational companies such as Siemens, General
Electric, Toshiba, Fuji, Elscint and Picker due, in part, to the high awareness
of such companys' brand name products. The Company seeks to compete with these
multinational firms by marketing a number of its products through Phillips GmbH,
Hamburg under the "Phillips" label.
Multinationals tend to concentrate marketing efforts primarily on large
companies who utilize high end systems and technologies as well as diagnosis
equipment such as computer tomography or magnetic resonance imaging systems with
costs in excess of $1,000,000 (and on occasion as high as $2,000,000) per
system. In fact, the strategy of one of these multinationals has been to
basically withdraw from developing and producing basic X-ray units for the
"basic" markets and to enter into an OEM agreement with the Company with respect
to its MRS unit which such multinational (Phillips GmbH, Hamburg) now sells
worldwide under its own label.
In addition to name recognition, competition is based on product features
and cost. The Company's newer products (i.e. Add-on Bucky and SwissVision)
compete by offering image digitalization, a feature normally available only on
high end products, such as CAT Scanners, at
14
<PAGE> 15
a lower cost. The Company believes that its products present the imaging market
with a unique balance of advanced features and low cost which will enable its
products to compete.
The Company's components are open systems, i.e. they can be used in
connection with competitor systems thereby allowing the Company to gain market
share within the replacement markets and to increasingly be accepted as a full
range hospital supplier for general radiology systems.
See also last full paragraph to Item 1, Description of Business - The
Company regarding certain additional competitive factors.
Employees
The Company employees approximately 59 persons and employs these persons
on the basis of standard employment agreements within the following categorical
functions:
No. of Employees
----------------
Operations: 18
Technical Services: 12
Finance & Administration: 6
Sales: 10
Marketing & Affiliates: 13
The Company attempts to remunerate its personnel in the usual labor market
demands and currently does not have any vacancies in strategic and/or management
positions.
In addition to the personnel indicated above, management estimates that
there are approximately 100 outside persons who work on Company products or
provide Company services in connection with its outsourcing policy.
Recent Developments
(a) In January 1996 the Company announced that it expected to install the
first of three Digital Imaging Add-on Bucky Systems at the Lagental Hospital in
Switzerland by the end of February 1996 having received purchase orders for
three such systems.
(b) In June of 1996 the Company announced that it had been awarded the
coveted ISO 9001 certification in recognition of its technological and
manufacturing performance. This certification, awarded by a private consortium,
is considered to be a highly regarded award within the international business
community.
(c) In June of 1996 the Company received an $8,000,000 contract from the
Swiss Federal State for delivery of conventional X-ray equipment to 21 hospitals
located within Eastern Europe.
15
<PAGE> 16
(d) In July of 1996 the Company retained the services of Needham and
Company, a full service banking company headquartered in New York City (with
additional offices in Boston and San Francisco) as the Company's financial
advisor, as same relates to future corporate strategies and potential
relationships (via merger, acquisition and/or partnership) within the United
States; the current primary objective being to assist the Company in selecting a
domestic (U.S.) strategic partner to market its digital X-ray technology
equipment within the U.S.
ITEM 2. DESCRIPTION OF PROPERTY
The Company's principal executive and operating offices, showroom and
demonstration facilities are located at Industriestrasse 6, 6285 Hitzkirch,
Switzerland and its telephone number is (011) 41 41 919 90 50. A new production
site was recently established in Hochdorf, Switzerland. Both locations are
within a couple of kilometers of each other.
The rental agreement for the Hitzkirch office expires in 2002 and is
indexed. The Hochdorf premise is going to be used mainly for final assembly and
testing and its rental agreement expires in 1999 with an option for
prolongation. No important capacity increase is deemed to be necessary for the
immediate foreseeable future as management considers its facilities to be
adequate for the Company's current and immediately foreseeable needs.
The facilities lease agreements provide for a base monthly payment of
$15,884 per month. Rent expense for the year ended 1996 was $242,658. See also
note 25 to the Company's consolidated financial statements for information with
respect to both rent expense payments for previous time periods as well as
future minimum annual lease payments.
ITEM 3. LEGAL PROCEEDINGS
The Company is not presently a party to any material litigation nor, to
the knowledge of management, is any material litigation threatened except as
indicated directly hereinunder.
On or about July 7, 1995, the Company commenced litigation against a
former officer and director of a corporate predecessor alleging certain
improprieties on the part of such officer and seeking monetary compensation as a
result thereof. Such defendant responded (in September 1995) by filing certain
affirmative defenses and counterclaims against the Company and others and
subsequently brought (together with certain of his family members) an action
against the Company in the same court which action raised issues and claims
substantially similar to those raised in the aforesaid counterclaims. The two
actions were assigned to the same judge and the Company moved successfully to
dismiss both the counterclaims and the second action. Leave to replead both
claims were granted and amended counterclaims and an amended complaint were
served and filed and the Company again successfully moved to dismiss both
pleadings. Following the most recent dismissal, counsel for the Company and the
aforesaid former officer entered into settlement discussions which continue to
date and to date no new pleadings have been served. Owing to the above set of
facts regarding the current status of the litigation and further owing to the
fact that discovery proceedings have not even been scheduled as yet, it is
virtually impossible to determine, with any degree of certainty, the final
outcome of this litigation
16
<PAGE> 17
although the Company fully expects to prevail on all material aspects of this
law suit.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The Company intends to hold its annual meeting of stockholders for its
fiscal year ended June 30, 1996 prior to the close of the current calendar year
but has not, as yet, formalized any specific plans as to any proposed date or
site (within or without the U.S.) for such meeting.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
(a) Marketing Information. The Company's common stock is listed on the
Nasdaq SmallCap Market and its securities are traded under the symbol SRMI. The
following table sets forth, for the periods indicated, the range of high and low
bid prices on the dates indicated for the Company's securities indicated below
for each full quarterly period within the two most recent fiscal years (if
applicable) and any subsequent interim period for which financial statements are
included and/or required to be included.
<TABLE>
<CAPTION>
Fiscal Year Ended June 30, 1995 Quarterly Common Stock Price
By Quarter (2) Ranges (1)
- ------------------------------------- ----------------------------
Quarter Date High Low
- ------- ---- ---- ---
<S> <C> <C> <C>
1st September 30, 1994 $1.50 $1.00
2nd December 31, 1994 $2.00 $1.0625
3rd March 31, 1995 $1.00 $ .625
4th June 30, 1995 $6.50 $1.00
</TABLE>
<TABLE>
<CAPTION>
Fiscal Year Ended June 30, 1996 Quarterly Common Stock Price
By Quarter Ranges (1)
- ------------------------------------- ----------------------------
Quarter Date High Low
- ------- ---- ---- ---
<S> <C> <C> <C>
1st September 30, 1995 (3) $6.8125 $6.00
2nd December 31, 1995 $7.875 $5.50
3rd March 31, 1996 (4) $7.25 $4.4375
4th June 30, 1996 (4) $6.50 $5.25
</TABLE>
<TABLE>
<CAPTION>
Fiscal Year Ended June 30, 1997 Quarterly Common Stock Price
By Quarter Ranges (1)
- ------------------------------------- ----------------------------
Quarter Date High Low
- ------- ---- ---- ---
<S> <C> <C> <C>
1st September 30, 1996 (4) $5.0625 $3.6875
</TABLE>
(1) The Company's common stock was assigned the symbol SRMI on the Electronic
Bulletin Board maintained by Nasdaq on June 13, 1995 and subsequently
began trading on the Nasdaq SmallCap market on March 20, 1996 with an
opening bid of $4.75. The following statement specifically refers to
Company common stock activity, if any, prior to March 20, 1996. The
existence of limited or sporadic quotations should not of itself be deemed
to constitute an "established public trading market". To the extent that
limited trading in the Company's
17
<PAGE> 18
Common Stock has taken place, such transactions have been limited to the
over-the-counter market except as otherwise indicated herein. Until March
20, 1996, all prices indicated herein are as reported to the Company by
broker-dealer(s) making a market in its securities in the National
Quotation Data Service ("pink sheets") and in the Electronic
Over-the-Counter Bulletin Board. Through such date the aforesaid
securities were not traded or quoted on any automated quotation system
other than as indicated herein. The over-the-counter market quotes
indicated above (as well as other quotes indicated above) reflect
inter-dealer prices, without retail mark-up, mark-down or commission, and
may not necessarily represent actual transactions.
(2) For the fiscal year ended June 30, 1995 (i.e. the four specific quarters
indicated above) reported trading volume exceeded 15,000 shares on only
approximately 13 occasions and for a substantial number of the trading
dates included during such fiscal year no trading volume whatsoever was
reported.
(3) During quarter ended September 30, 1995 reported trading volume exceeded
15,000 shares on only approximately 1 occasion and for a majority of such
trading dates included during such quarter no trading volume whatsoever
was reported.
(4) As heretofore indicated in footnote 1 hereto, the Company's common stock
commenced trading on the Nasdaq SmallCap market on March 20, 1996. From
April 1, 1996 to September 30, 1996 daily average total volume as reported
on the summary of activity provided by Nasdaq on a monthly basis was as
follows: April 1996 - 79,479, May 1996 - 75,506, June 1996 - 54,993 and
July 1996 - 56,663 while such volume decreased during the summer months of
August 1996 and September 1996 to 21,820 and 25,881 respectively.
(b) Holders. As of October 2, 1996 the approximate number of stockholders
of the Company's Common Stock (as indicated on its transfer agent's October 2,
1996 certified list of stockholders) amounted to 770 persons and/or firms
(inclusive of those brokerage firms and/or clearing houses and/or depository
companies holding the Company's securities for their respective clientele - each
such brokerage house, clearing house and/or depository firm being considered as
one record holder). The exact number of beneficial owners of the Company's
securities is not known but would necessarily exceed the number of record owners
indicated above in that brokerage firms and/or clearing house and/or depository
companies are normally record owners for presumably any number of unidentified
beneficial owners.
(c) Dividends. The payment by the Company of dividends, if any, in the
future rests within the discretion of its Board of Directors and will depend,
among other things, upon the Company's earnings, its capital requirements and
its financial condition, as well as other relevant factors. The Company has not
paid or declared any dividends upon its Common Stock since its inception and, by
reason of its present financial status and its contemplated financial
requirements , does not contemplate or anticipate paying any dividends upon its
Common Stock in the foreseeable future.
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Background
The Company acquired it wholly owned subsidiary, SR-Medical AG, in June of
1995 in exchange for 7,000,000 shares of its common stock. The merger between
the Company and SR- Medical AG is considered for accounting purposes to be a
recapitalization of SR-Medical AG with SR-Medical AG as the acquirer. The
consolidated financial statements for all periods presented take into account
SWISSRAY International, Inc. - the Parent - (from June 6, 1995
18
<PAGE> 19
through June 30, 1996), SR-Medical AG, Telray AG, SR Medical GmbH and SR Finance
AG.
This discussion summarizes the significant factors affecting the
consolidated operating results, financial condition and liquidity/cash flows of
the Company during the fiscal year ended June 30, 1996 and the 18 month period
ended June 30, 1995 (with respect to the Company's consolidated balance sheets)
and such comparative periods as are practicable based upon information appearing
in the Company's consolidated statements of operations and related financial
statements and/or notes thereto and should be read in conjunction with such
consolidated financial statements and notes thereto included in its report.
The Company changed its year end from calendar year ended December 31 to
fiscal year ended June 30 and June 30, 1996 represents the first instance when
such fiscal year has been utilized. Accordingly, the consolidated statements of
operations do not contain comparative information for fiscal year ended June 30,
1996 with the 12 month period ended June 30, 1995.
The Company, operating through its subsidiaries (i.e., its wholly owned
subsidiary, SR-Medical AG, and the latter's wholly owned subsidiaries, Teleray
AG (a Swiss corporation) and SR-Medical GmbH (a German corporation), (as well as
through the Company's wholly owned subsidiary, SR Finance AG, a Swiss
corporation) remains engaged in the diagnostic X-ray medical equipment market,
wherein it develops, assembles and sells worldwide, both directly and indirectly
under its label SWISSRAY as well as to Original Equipment Manufacturers (OEM)
partners, X-ray units and accessories. Recently, substantial efforts have been
concentrated upon its newly developed digital imaging processing system called
"SwissVision" designed to enhance X-ray diagnosis with computer assistance by
(integrating computer technology with radiology in order to support the
radiologist in diagnostic functions) utilizing a Digital, recently developed,
"Add-on" Bucky which allows for direct digitalization of the radiology process
(and eliminates the need for the use and subsequent storage and/or retrieval of
X-ray film). In that respect and as hereinafter indicated, the Company has
expended during fiscal year ended June 30, 1996, in excess of $1,700,000 for
research and development expenditures, which expenditures accounted for
approximately 20% of all operating expenses during fiscal year ended June 30,
1996.
Consolidated Statements of Operations
Net sales for the fiscal year ended June 30, 1996 were $10,899,222 while
costs of sales amounted to $5,793,306 resulting in a gross profit of $5,105,916
(i.e. approximating 47% of net sales). Operating expenses totalled $8,591,679
with the two principal expenses of salaries (exclusive of officers and directors
compensation) and research and development accounting for approximately 21% and
20% of such operating expenses. Accordingly, an aggregate of $3,561,037 (41%) of
all operating expenses are attributed to these two principal operating expense
items. Primarily as a result of the above (and after taking into account certain
other income, losses from continuing operations and after giving effect to
certain extraordinary items the Company incurred a net loss for fiscal year
ended June 30, 1996 of $(1,891,612); an amount fairly comparable to the amount
spent on the research and development operating expenses heretofore referred to.
While there are no comparative results in the consolidated statements of
operations for the 12 month period ended June 30, 1995 (due to change in Company
year end)
19
<PAGE> 20
the aforesaid research and development expense of $1,731,502 is $1,394,743 more
than the aggregate of $336,759 spent during the preceding 18 month period (i.e.
January 1, 1994 to June 30, 1995) on research and development. The in excess of
400% increase in research and development expense during fiscal year ended June
30, 1996 as compared to the preceding 18 month period may be primarily
attributable to the Company's on-going efforts to further develop and improve
upon the qualities of its SwissVision and Add-on Bucky and related computer
programs and peripherals.
Consolidated Balance Sheets
Total Assets of the Company at periods ended June 30, 1996 and June 30,
1995 were $18,793,438 and $13,027,356 respectively; an increase of $5,766,082.
Total Current Assets increased by $4,440,278 (as a result of increases in (a)
cash and cash equivalents of $575,859, (b) various accounts receivables of
$504,862, (c) notes receivable of $962,500, (d) inventories of $1,420,393 and
(e) prepaid expenses of $976,664) while property and equipment increased by
$790,583 and Other Assets increased by $535,221 (principally as a result of an
increase in long-term accounts receivable of $1,038,693 which more than offset
decreases of (a) $175,646 in due from stockholders, officers and affiliates and
(b) $372,493 in Licensing Agreement.
Total Current Liabilities of the Company at periods ended June 30, 1996
and June 30, 1995 respectively were $8,138,182 and $5,945,488 respectively; an
increase of $2,192,694 which increase is attributable to increases in (a)
accounts payable of $1,514,465, (b) accrued expenses of $855,041, (c) current
maturities of long-term debt of $424,031, (d) customer deposits of $38,874 and
(e) accounts payable - affiliates of $1,541 offset by decreases in notes
payable-banks and loan payable - aggregating $641,258.
At June 30, 1996 there were no long term liabilities as the long term
liabilities of the preceding 12 months which then amounted to $705,035 were
either repaid (as to $281,004) or are now listed under current liabilities (as
to the balance of $511,101) as current maturities of long term debt.
Working capital at June 30, 1996 was $3,432,732 as compared to working
capital of $1,185,148 at June 30, 1995; an increase of $2,247,584 (primarily for
the reasons indicated herein).
The functional currencies of SR Medical AG, Teleray AG and SR Finance AG
(Swiss corporations) are Swiss Francs while the functional currency of SR
Medical GmbH (a German corporation) is German Marks. Gains and losses resulting
from foreign currency transactions which are included in operations have been
insignificant for all periods reported. However, the effects of exchange rate
fluctuations on translating foreign currency assets and liabilities and results
of operations from functional currency to Unites States dollars has been
significant. The cumulative foreign currency translation adjustment (loss) to
stockholders' equity has increased from $(436,180) at June 30, 1995 to
$(836,047) at June 30, 1996.
20
<PAGE> 21
Financing
Raising of capital required to finance the proposed growth out of cash
flow over an approximate 5 year period has been accomplished during fiscal year
ended June 30, 1996 through (a) sale and issuance of 1,100,000 shares of Company
common stock for an aggregate cash consideration of $5,200,000 and (b) receipt
of $2,050,000 as a result of options exercised for the purchase of 1,050,000
shares of Company common stock.
The Company maintains a line of credit with a leading Swiss financial
institution for $798,100 in excess of cash balances on deposit, which cash
balances amounted to $1,596,200 as of June 30, 1996.
From time to time certain Company stockholders, officers and/or affiliates
have received sums of money from the Company as unsecured advances. The balance
due to the Company, as at June 30, 1996 was $204,090 as compared to $379,736 as
of June 30, 1995.
When considering the fact that working capital as of June 30, 1996
amounted to $3,432,732 management of the Company does not envision any
immediately foreseeable material liquidity and/or capital resource problems.
Management does not anticipate any significant long term liquidity needs and
anticipates being able to finance long term operations through income derived
from sale of its new (Add-on Bucky and related SwissVision) products. However,
if an unforeseen need arises, management contemplates being able to satisfy same
through an as yet undetermined combination of debt and/or equity financing
and/or bank loans.
Recent Developments, Backlog and Projections
An installation of the Company's Add-on Bucky was effectuated in April-May
1996 in the Radiology Department of a hospital located in Langenthal,
Switzerland. As a result of such successful installation, management anticipates
additional installations will be made in the near future at comparable
facilities and other reference sites in different countries. Management expects
to receive significant orders for Add-on Bucky and SwissVision in the coming
month(s) and further expects to be able to commence significant deliveries in
the last quarter of this year. It is expected that these anticipated deliveries
will result in substantially increased revenues and a corresponding increase in
profit margins.
Management believes that at the present time there is no significant
competition for the Company's Add-on Bucky within its designated market segment.
At the recent Radiological Society of North American show, only one other firm
was exhibiting a product for filmless digitalization of a x-ray image but did
not expect to commence marketing prior to 1998/99, thereby leaving the Company
with an approximate two year market lead advantage. Management expects that the
technological developments incorporated in its Add-on Bucky will enable the
Company to eventually become a leading supplier of both conventional and digital
x-ray systems for hospitals, small and medium sized radiology centers and/or
individual doctors and accordingly made a major expenditure of in excess of
$1,700,000 (approximately 20% of all operating costs
21
<PAGE> 22
for fiscal year ended June 30, 1996) towards future research and development in
this and related areas.
Management is currently evaluating certain potential strategic
relationships within the U.S. with certain multinational companies who have
expressed an interest in the Company's digital imaging systems. Successful
culmination of ongoing negotiations would enable the Company to sell its
products under its own brand name, through partnerships and/or joint ventures
and/or through OEM Partners thereby potentially opening more markets to the
Company than currently exist. At the same time, and throughout Europe and Asia,
the Company intends to continue to develop its relationships within its own
marketing network and with additional OEM Partners.
The Company has recently (primarily during the fourth quarter of its
fiscal year ended June 30, 1996) increased its staff in the areas of project
management, research and development and in the assembly production center in
order to comply with projected increased production output requirements.
Correspondingly, its sales organization has been enlarged with additional
offices and sales staff in place in Europe, with further expansion planned for
the U.S. during fiscal year ended June 30, 1997.
Sales continue to grow with orders from the Swiss Government for Eastern
European countries and the continued existence and expansion upon the Phillips
contract with revenues estimated at $40,000,000 over the next four years. Order
backlog (by the end of June 1996) is in excess of $25,000,000 for conventional
X-ray equipment and approximately $30,000,000 for the digital Add-on Bucky and
related paraphernalia. Management anticipates the need for lead time of
approximately 12 to 18 months in order to comply with and fulfill these orders.
As a result of significant research and development expenditures, new products
are being successfully developed for marketing. Once such product is the
floating table with tomographic picture acquiring technique. Other products
expected to be marketed are intended to incorporate innovative solutions in
order to simplify and make conventional X-ray technology more efficient. These
developments were made possible due to a strong research and development
department and the expenditures incurred therein as well as in cooperation with
OEM partners like Phillips.
The Company has incurred delay in the production of the Add-on Bucky due
to the need to optimize all components of this high technology picture acquiring
device reflecting the limits of current feasible technological possibilities in
the field of chips, camera and optics. A high resolution has now been reached of
2048 x 1750 pixels and is very well qualified to do high resolutions exams.
Company products have received endorsements from hospitals, doctors and the
press and the Add-on Bucky has received the European approvals indicating that
it has met the technical requirements of the EEC countries. It is expected that
the revenues from the Add-on Bucky will be generated initially in Europe and
hopefully in the U.S. once FDA approval is received.
Production of the Add-on Bucky has commenced and management expects to be
in a position to deliver products within the next three months with the
expectation that such delivery will result in significant revenues and the
requirements of increased production in order to meet
22
<PAGE> 23
anticipated demand for such product(s).
ITEM 7. FINANCIAL STATEMENTS
The following financial statements have been prepared in accordance with
the requirements of Regulation S-B and supplementary financial information
included herein, if any, has been prepared in accordance with Item 302 of
Regulation S-K, such information appears on pages F-1 through F-15 inclusive for
fiscal years ended June 30, 1996 and 1995 of this Form 10- KSB, which pages
follow this page.
SWISSRAY INTERNATIONAL, INC.
JUNE 30, 1996 AND 1995
CONTENTS
Page
----
Independent Auditor's Report F-1
Consolidated Balance Sheets F-2
Consolidated Statements of Operations F-3
Consolidated Statements of Stockholders' Equity F-4
Consolidated Statements of Cash Flows F-5
Notes to Consolidated Financial Statements F-6 - F-15
23
<PAGE> 24
[BEDERSON & COMPANY LETTERHEAD]
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholders
Swissray International, Inc.
New York, New York
We have audited the accompanying consolidated balance sheets of Swissray
International, Inc., and its subsidiaries, as of June 30, 1996 and 1995, and the
related consolidated statements of operations, stockholders' equity and cash
flows for the years ended June 30, 1996 and December 31, 1994 and the six months
ended June 30, 1995. These consolidated financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the consolidated financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the 1996, 1995 and 1994 consolidated financial statements
referred to above present fairly, in all material respects, the financial
position of Swissray International, Inc., and its subsidiaries, at June 30, 1996
and 1995 and the results of their operations and their cash flows for the years
ended June 30, 1996 and December 31, 1994 and the six months ended June 30,
1995, in conformity with generally accepted accounting principles.
BEDERSON & COMPANY LLP
/s/ Bederson & Company LLP
West Orange, New Jersey
September 20, 1996
F(1)
<PAGE> 25
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
JUNE 30, 1996 AND 1995
ASSETS
<TABLE>
<CAPTION>
1996 1995
----------- -----------
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 3,252,685 $ 2,676,826
Accounts receivable, net of allowance for doubtful
accounts of $109,843 for 1996 and $73,137 for 1995 3,335,679 2,840,212
Accounts receivable - affiliates 31,533 --
Accounts receivable - other -- 22,138
Note receivable 962,500 --
Inventories 2,912,836 1,492,443
Prepaid expenses and sundry receivables 1,075,681 99,017
----------- -----------
TOTAL CURRENT ASSETS 11,570,914 7,130,636
----------- -----------
PROPERTY AND EQUIPMENT 1,138,282 347,699
----------- -----------
OTHER ASSETS:
Due from stockholders 17,414 154,114
Due from officers -- 4,354
Due from affiliates 186,676 221,268
Accounts receivable - long-term, net of discount and
allowance for doubtful account of $300,000 1,038,693 --
Licensing agreement, net of accumulated amortization
of $372,493 for June 1996 4,594,082 4,966,575
Patents and trademarks, net of accumulated
amortization of $28,001 for June 1996 220,018 202,710
Organization cost, net of accumulated amortization
of $978 for June 1996 7,407 --
Security deposits 19,952 --
----------- -----------
TOTAL OTHER ASSETS 6,084,242 5,549,021
----------- -----------
TOTAL ASSETS $18,793,438 $13,027,356
=========== ===========
</TABLE>
LIABILITIES AND STOCKHOLDERS' EQUITY
<TABLE>
<S> <C> <C>
CURRENT LIABILITIES:
Current maturities of long-term debt $ 511,101 $ 87,070
Notes payable - banks 2,069,828 2,709,965
Loan payable 156,254 157,375
Accounts payable 4,186,092 2,671,627
Accounts payable - affiliates 1,541 --
Accrued expenses 1,135,693 280,652
Customer deposits 77,673 38,799
------------ ------------
TOTAL CURRENT LIABILITIES 8,138,182 5,945,488
------------ ------------
LONG-TERM DEBT, less current maturities -- 705,035
------------ ------------
STOCKHOLDERS' EQUITY:
Common stock 141,851 120,351
Additional paid-in capital 19,268,400 12,719,998
Accumulated deficit (7,918,948) (6,027,336)
Cumulative foreign currency translation adjustment (836,047) (436,180)
------------ -------------
TOTAL STOCKHOLDERS' EQUITY 10,655,256 6,376,833
------------ -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 18,793,438 $ 13,027,356
============ =============
</TABLE>
The accompanying notes are an integral part of these
financial statements.
F(2)
<PAGE> 26
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------ ----------- -----------
<S> <C> <C> <C>
NET SALES $ 10,899,222 $ 3,806,313 $ 8,617,604
COST OF SALES 5,793,306 2,484,253 5,362,698
------------ ----------- -----------
GROSS PROFIT 5,105,916 1,322,060 3,254,906
------------ ----------- -----------
OPERATING EXPENSES:
Officers and directors compensation 612,776 155,214 275,512
Salaries 1,829,535 734,389 1,127,474
Selling 1,140,604 619,735 507,783
Research and development 1,731,502 233,084 103,675
General and administrative 1,161,291 55,684 149,061
Other operating expenses 1,098,346 453,934 748,157
Bad debts 491,487 30,847 223,084
Depreciation and amortization 526,138 24,344 40,523
------------ ----------- -----------
TOTAL OPERATING EXPENSES 8,591,679 2,307,231 3,175,269
------------ ----------- -----------
INCOME (LOSS) BEFORE OTHER
INCOME (EXPENSES) AND INCOME
TAXES (3,485,763) (985,171) 79,637
OTHER INCOME (EXPENSES) 810,003 (3,175,644) (252,117)
------------ ----------- -----------
LOSS FROM CONTINUING OPERATIONS
BEFORE INCOME TAXES AND
EXTRAORDINARY ITEMS (2,675,760) (4,160,815) (172,480)
INCOME TAX PROVISION (BENEFIT) (364,648) (338,975) 24,112
------------ ----------- -----------
LOSS FROM CONTINUING OPERATIONS
BEFORE EXTRAORDINARY ITEMS (2,311,112) (3,821,840) (196,592)
EXTRAORDINARY ITEMS, net of income tax
of approximately $343,000 for 1996 and
$340,000 for 1995 419,500 415,695 --
------------ ----------- -----------
NET LOSS $ (1,891,612) $(3,406,145) $ (196,592)
============ =========== ===========
LOSS PER COMMON SHARE:
Loss from continuing operations $ (.18) $ (.18) $ (.03)
Extraordinary item .03 .05 --
------------ ----------- -----------
NET LOSS $ (.15) $ (.13) $ (.03)
============ =========== ===========
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING 12,926,722 8,017,242 7,850,064
============ =========== ===========
</TABLE>
The accompanying notes are an integral part of these
financial statements.
F(3)
<PAGE> 27
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
Cumulative
Foreign
Common Stock Additional Currency
----------------------- Paid-in Accumulated Translation
Shares Amount Capital Deficit Adjustment
---------- -------- ------------ ----------- -----------
<S> <C> <C> <C> <C> <C> <C>
BALANCE - January 1, 1994 7,850,064 $ 78,501 $ 1,911,848 $(2,424,599) $ 4,893
For year ended December 31, 1994:
Foreign currency translation adjustment -- -- -- -- (172,550)
Net loss for the year -- -- -- (196,592) --
---------- -------- ------------ ----------- ---------
BALANCE - December 31, 1994 7,850,064 78,501 1,911,848 (2,621,191) (167,657)
For the six months ended June 30, 1995:
Issuance of common stock for services 1,525,000 15,250 3,034,750 -- --
Issuance of common stock for licensing agreement 660,000 6,600 3,793,400 -- --
Issuance of common stock for cash 2,000,000 20,000 3,980,000 -- --
Foreign currency translation adjustment -- -- -- -- (268,523)
Net loss of the period -- -- -- (3,406,145) --
---------- -------- ------------ ----------- ---------
BALANCE - June 30, 1995 12,035,064 120,351 12,719,998 (6,027,336) (436,180)
Issuance of common stock for cash 1,100,000 11,000 5,189,000 -- --
Stock options exercised for cash 1,050,000 10,500 2,039,500 -- --
Foreign currency translation adjustment -- -- -- -- (399,867)
Public offering expenses -- -- (680,098) -- --
Net loss for the year -- -- -- (1,891,612) --
---------- -------- ------------ ----------- ---------
BALANCE - June 30, 1996 14,185,064 $141,851 $ 19,268,400 $(7,918,948) $(836,047)
========== ======== ============ =========== =========
</TABLE>
<TABLE>
<CAPTION>
Total
------------
<S> <C> <C>
BALANCE - January 1, 1994 $ (429,357)
For year ended December 31, 1994:
Foreign currency translation adjustment (172,550)
Net loss for the year (196,592)
------------
BALANCE - December 31, 1994 (798,499)
For the six months ended June 30, 1995:
Issuance of common stock for services 3,050,000
Issuance of common stock for licensing agreement 3,800,000
Issuance of common stock for cash 4,000,000
Foreign currency translation adjustment (268,523)
Net loss of the period (3,406,145)
------------
BALANCE - June 30, 1995 6,376,833
Issuance of common stock for cash 5,200,000
Stock options exercised for cash 2,050,000
Foreign currency translation adjustment (399,867)
Public offering expenses (680,098)
Net loss for the year (1,891,612)
------------
BALANCE - June 30, 1996 $ 10,655,256
============
</TABLE>
The accompanying notes are an integral part of these
financial statements.
F(4)
<PAGE> 28
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------- ------------- ------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(1,891,612) $(3,406,145) $ (196,592)
Adjustment to reconcile net loss to net
cash from operating activities:
Depreciation and amortization 526,138 24,344 40,523
Provision for bad debts 336,706 30,847 223,084
Gain on extinguishment of debt -- (755,695) --
Gain on sale of marketable securities (762,500) -- --
Foreign currency translation 273,137 (129,282) (193,378)
Operating expenses through issuance of common stock -- 3,050,000 --
(Increase) decrease in operating assets:
Accounts receivable (1,870,866) (2,199,013) 205,631
Accounts receivable - affiliates (31,533) -- --
Accounts receivable - other 22,138 742,262 (628,316)
Inventories (1,420,393) (38,806) (206,536)
Prepaid expenses and sundry receivables (976,664) (40,533) 56,595
Increase(decrease) in operating liabilities:
Accounts payable 1,514,465 1,361,262 24,500
Accounts payable - affiliates 1,541 -- --
Accrued expenses 855,041 156,681 (54,376)
Customer deposits 38,874 38,799 --
----------- ----------- -----------
NET CASH USED BY OPERATING ACTIVITIES (3,385,528) (1,165,279) (728,865)
----------- ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment (932,066) (80,714) (88,600)
Licensing agreement -- (885,571) --
Purchase of marketable securities (200,000) -- --
Patents and trademarks (45,309) -- --
Organization cost (8,385) -- --
Investments in affiliates -- -- 23,989
Security deposits (19,952) -- --
Repayments from affiliates 34,592 4,906 32,604
----------- ----------- -----------
NET CASH USED BY INVESTING ACTIVITIES (1,171,120) (961,379) (32,007)
----------- ----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term borrowing 2,069,828 2,730,898 2,728,093
Proceeds from long-term borrowing -- 90,681 83,720
Principal payment of short-term borrowings (2,711,086) (1,950,393) (2,030,574)
Principal payments of long-term borrowing (281,004) -- --
Issuance of common stock for cash 7,250,000 4,000,000 --
Repayment from (advances to) stockholder 136,700 (16,522) (83,720)
Repayment from (advances to) officer 4,354 (4,354) --
Public offering expenses (680,098) -- --
----------- ----------- -----------
NET CASH PROVIDED BY FINANCING ACTIVITIES 5,788,694 4,850,310 697,519
----------- ----------- -----------
EFFECT OF EXCHANGE RATE CHANGES ON CASH (656,187) (139,241) 20,828
----------- ----------- -----------
NET INCREASE (DECREASE) IN CASH 575,859 2,584,411 (42,525)
CASH AND CASH EQUIVALENTS - beginning of period 2,676,826 92,415 134,940
----------- ----------- -----------
CASH AND CASH EQUIVALENTS - end of period $ 3,252,685 $ 2,676,826 $ 92,415
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these
financial statements.
F(5)
<PAGE> 29
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION
The Company was incorporated under the laws of the State of New York on
January 2, 1968 under the name "C.G.S. Units, Inc." On May 23, 1994, the
Company acquired 100% of the outstanding securities of Direct Marketing
Services, Inc., a company incorporated in the State of Delaware on June
3, 1993. On June 6, 1994, the Company merged with Direct Marketing
Services, Inc. and the surviving corporation changed its' name to DMS
Industries, Inc. DMS Industries, Inc. was principally engaged in the
promotion and sales of its proprietary brand of cigarettes on a
commission basis. In May of 1995 the Company discontinued its'
operations and changed its' name to Swissray International, Inc.
PRINCIPLES OF CONSOLIDATION
The accompanying consolidated financial statements include the accounts
of Swissray International, Inc. (Parent), and its' wholly owned
subsidiaries SR Medical AG and SR Finance AG (both Swiss corporations)
and SR Medical AG's wholly owned subsidiaries Teleray AG (a Swiss
Corporation) and SR Medical GmbH (a German corporation). All material
intercompany transactions and balances have been eliminated in
consolidation.
BUSINESS COMBINATION AND RESTATEMENT
On June 6, 1995, Swissray International, Inc. exchanged 7,000,000 shares
of common stock for all of the outstanding shares of SR Medical AG. The
merger between Swissray International Inc. and SR Medical AG is
considered for accounting purposes to be a recapitalization of SR
Medical AG with SR Medical AG as the acquirer. The consolidated
financial statements for all periods presented include the accounts of
Swissray International, Inc. (from June 6, 1995 thru June 30, 1996), SR
Medical AG, Teleray AG, SR Medical GmbH and SR Finance AG. The
stockholders' equity of SR Medical AG has been retroactively restated
for the equivalent number of shares received in the merger.
SR Medical AG (a Swiss corporation) was organized in 1988 and develops,
assembles and markets diagnostic x-ray medical equipment.
Teleray AG (a Swiss corporation) was organized in 1994 and is engaged in
research and development activities related to diagnostic x-ray medical
equipment and accessories.
SR Medical GmbH (a German corporation) was organized in 1988 and is
engaged in sales and marketing of diagnostic x-ray medical equipment and
accessories.
SR Finance AG (a Swiss corporation) was organized in December of 1995 as
a service oriented company serving only the other companies within the
consolidated group in the areas of consultation, bookkeeping, logistics,
and employment services.
BASIS OF ACCOUNTING
The Company maintains its records on the accrual basis of accounting.
Revenues are recognized when the products are delivered and expenses are
recorded when incurred.
CHANGES IN ACCOUNTING YEAR
On July 7, 1995 the Board of Directors approved the changing of the
Company's accounting year from December 31 to a June 30 fiscal year end.
CERTAIN SIGNIFICANT RISK AND UNCERTAINTIES
The preparation of financial statements in conformity with generally
accepted accounting principles require management to make estimates and
assumptions that effect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenue and expenses
during this period. Actual results could differ from those estimates.
CASH EQUIVALENTS
The Company considers all highly liquid investments purchased with an
original maturity of three months or less to be cash equivalents.
F(6)
<PAGE> 30
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 1 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
INVENTORIES
Inventories are stated at lower of cost or market, with cost being
determined on the first-in, first-out (FIFO) method. Inventory cost
include material, labor, and manufacturing overhead.
PROPERTY AND EQUIPMENT
Property and equipment including significant betterments, are recorded
at cost. Upon retirement or disposal of properties, the cost and
accumulated depreciation are removed from the accounts, and any gain or
loss is included in income. Maintenance and repair costs are charged to
expense as incurred.
DEPRECIATION
Depreciation of property and equipment is provided for over the
estimated useful lives of the respective assets. Depreciation is
recorded on the straight-line method. The estimated useful lives of each
asset category are as follows:
Years
-----
Equipment 5 - 10
Office furniture and equipment 5 - 10
Leasehold improvements 10
INTANGIBLE ASSETS
Patents and trademarks are stated at cost less accumulated amortization
computed on the straight-line method over its estimated economic life of
10 years. Amortization commenced on July 1, 1995, therefore, no
amortization expense has been provided for the year ended December 31,
1994 and for the six months ended June 30, 1995. Amortization expense,
for patents and trade marks, for the year ended June 30, 1996 was
$28,001.
Licensing agreement is stated at fair value (cost less imputed interest)
net of accumulated amortization computed on the straight-line method
over its estimated economic life of 10 years. Amortization commenced on
October 1, 1995 upon the initial sale of the Company's products within
the defined territories of the agreement. No amortization expense has
been provided for the year ended December 31, 1994 and the six months
ended June 30, 1995. Amortization expense, for licensing agreement, for
the year ended June 30, 1996 was $372,493.
All cost incurred by the Company in connection with incorporation of
subsidiaries have been capitalized and are being amortized over a period
of sixty (60) months. Amortization expense, for organization cost, for
the year ended June 30, 1996 was $978 and for the six months ended June
30, 1995 and year ended December 31, 1994 were $-0-.
RESEARCH AND DEVELOPMENT
Cost associated with research, new product development, and product cost
improvements are treated as expenses when incurred. Research and
development costs expended for the year ended June 30, 1996, six months
ended June 30, 1995, and year ended December 31, 1994 were $1,731,502,
$233,084 and $103,675, respectively.
EXPENSES RELATED TO SALES AND ISSUANCE OF SECURITIES
All costs incurred in connection with the sale of the Company's common
stock have been capitalized and charged to additional paid-in capital.
NET LOSS PER COMMON SHARE
Loss per common share is computed by dividing the net loss by the
weighted average number of shares of common stock outstanding during the
periods.
F(7)
<PAGE> 31
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 1 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
FOREIGN CURRENCY TRANSLATION
Assets and liabilities of subsidiaries operating in foreign countries
are translated into U.S. dollars using the exchange rate in effect at
the balance sheet date. Results of operations are translated using the
average exchange rates prevailing throughout the year. The effects of
exchange rate fluctuations on translating foreign currency assets and
liabilities into U.S. dollars are included in stockholders' equity,
while gains and losses resulting from foreign currency transactions are
included in operations.
NOTE 2 -CONCENTRATION OF CREDIT RISK AND RISK ARISING FROM CASH DEPOSITS IN
EXCESS OF INSURED LIMITS
The Company sells its products to various customers primarily in Europe,
Asia and Africa. The Company performs ongoing credit evaluations on its
customers and generally does not require collateral. The Company
maintains reserves for potential credit losses and such losses have been
within management's expectations.
The Company maintains its cash balances with major Swiss financial
institutions. The cash balances at June 30, 1996 are not insured.
NOTE 3 -DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company measures its financial assets and liabilities in accordance
with generally accepted accounting principles. For certain of the
Company's financial instruments, including cash and cash equivalents,
trade and other accounts receivable, notes receivable, accounts payable,
accrued expenses, notes and loans payable, the carrying amounts
approximate fair value due to their short term maturities. The amount
shown for long-term receivables also approximate fair value.
Investments in affiliated companies for which there is no quoted market
price are accounted for by the equity method resulting in no carrying
value which the Company considers a fair value.
NOTE 4 -ACCOUNTS RECEIVABLE - AFFILIATES
The Company has sold merchandise to affiliated sales companies in the
normal course of business. The amounts due to the Company at June 30,
1996 were $31,533.
NOTE 5 -ACCOUNTS RECEIVABLE - LONG-TERM
The Company sold merchandise to a customer in 1995 and in 1996
negotiated payment terms over an extended period of time. The agreed
upon terms require the customer to pay the Company approximately $5,000
to $30,000 per month. The balance at June 30, 1996 was $1,038,693 after
applying a discount for imputed interest and a provision for doubtful
collection.
NOTE 6 -NOTE RECEIVABLE
On June 20, 1996 the Company sold marketable securities for a 5%
promissory note in the amount of $962,500 due on October 20, 1996.
F(8)
<PAGE> 32
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 7 -DUE FROM AFFILIATES
The Company has made non-interest bearing advances to affiliated sales
companies as follows:
<TABLE>
<CAPTION>
June 30,
--------------------
1996 1995
-------- --------
<S> <C> <C>
Swissray Medical GmbH, Willich $186,676 $180,455
Teleray S.R.O. Brno -- 34,199
-------- --------
$186,676 $214,654
======== ========
</TABLE>
NOTE 8 -INVENTORIES
Inventories are summarized by major classification as follows:
<TABLE>
<CAPTION>
June 30,
------------------------
1996 1995
---------- ----------
<S> <C> <C>
Raw materials, parts and supplies $1,854,322 $ 945,257
Work-in process 853,657 130,605
Finished goods 204,857 416,581
---------- ----------
$2,912,836 $1,492,443
========== ==========
</TABLE>
NOTE 9 -PROPERTY AND EQUIPMENT
<TABLE>
<CAPTION>
June 30,
----------------------
1996 1995
---------- --------
<S> <C> <C>
Equipment $1,031,849 $140,407
Office furniture and equipment 121,404 145,840
Leasehold improvements 219,024 153,964
---------- --------
1,372,277 440,211
Less: Accumulated depreciation
and amortization 233,995 92,512
---------- --------
$1,138,282 $347,699
========== ========
</TABLE>
Depreciation and amortization expense, for property and equipment, for
the years ended June 30, 1996, six months ended June 30, 1995 and year
ended December 31, 1994 were $103,176, $24,344 and $40,523,
respectively.
NOTE 10-DUE FROM STOCKHOLDER
The Company has made unsecured advances to its' President (a principal
stockholder) requiring interest only payments at 6% per annum. The
balance at June 30, 1996 and 1995 was $17,414 and $154,114,
respectively. Interest charged the stockholder for the year ended June
30, 1996, for the six months ended June 30, 1995 and for the year ended
December 31, 1994 were $12,530, $2,312 and $5,744, respectively.
NOTE 11-DUE FROM OFFICER
In June of 1995, the Company made an unsecured advance to an officer in
the amount of $4,354 requiring interest only payments at 6% per annum.
The advance was repaid in 1996.
F(9)
<PAGE> 33
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 12-INVESTMENTS
The Company has made various investments which are recorded on the
equity method. These entities have operated at a loss in excess of
equity, therefore, the Company is carrying these investments as follows:
<TABLE>
<CAPTION>
Ownership Cost at Carrying
% June 30, 1996 Value
--------- ------------- --------
<S> <C> <C> <C>
Swissray SR Medical GmbH, Willich 34% $16,892 $ --
Swissray Medical, s.r.o., Bratislaua 34% 6,757 --
Swissray Medical s.r.o., Brno 34% 6,757 --
Teleray s.r.o., Willich 49% 28,362 --
Teleray s.r.o., Brno 34% 6,757 --
Digitec GmbH, Neuss 20% 11,484 --
------- -------
Total $77,009 $ --
======= =======
</TABLE>
NOTE 13-LICENSING AGREEMENT
The Company entered into a licensing agreement in June of 1995 with an
unaffiliated individual. The agreement is for an exclusive field-of-use
license within the United States and Canada to use the proprietary
information, including the patent rights, for certain technology
regarding the integration of computer technology with diagnostic x-ray
and radiology medical equipment through digital imaging systems. The
agreement required a fee of $5,000,000 consisting of $1,200,000 in cash
and 660,000 shares of the Company's common stock. The cash payment
requirement consisted of $900,000 upon the signing of the agreement and
the $300,000 balance due on December 31, 1996. The fee has been
discounted at 7.5% for imputed interest of $33,425 resulting in a net
capitalized cost of $4,966,575. This agreement is for an indefinite term
or until all of the proprietary information becomes public knowledge and
the patent rights expire.
NOTE 14-NOTES PAYABLE - BANK
The Company has negotiated a line-of-credit agreement with the Union
Bank of Switzerland for $798,100, based on the exchange rate in effect
on June 30, 1996, in excess of cash balances on deposit with the bank.
The line-of-credit is secured by accounts receivable. Cash balances on
deposit at June 30, 1996 with the bank were $1,596,200.
Notes payable are summarized as follows:
<TABLE>
<CAPTION>
June 30,
------------------------
1996 1995
---------- ----------
<S> <C> <C>
Union Bank of Switzerland, due on demand,
with interest at 8% per annum, collateralized
by accounts receivable $2,069,828 $1,711,255
Credit Suisse Bank, due on demand, with
interest at 8% per annum, collaterized by
accounts receivable -- 905,570
Cantonal Bank of Lucerne, due on demand, with
interest at 8% per annum, collateralized by
accounts receivable -- 93,140
---------- ----------
$2,069,828 $2,709,965
========== ==========
</TABLE>
NOTE 15-LOAN PAYABLE
The Company has negotiated a 5% demand loan from a private foundation
fund. The balance at June 30, 1996 and 1995 were $156,254 and $157,375,
respectively.
F(10)
<PAGE> 34
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 16-LONG-TERM DEBT
Long-term debt consists of the following:
<TABLE>
<CAPTION>
June 30,
--------------------
1996 1995
-------- --------
<S> <C> <C>
Note payable - licensing agreement, due
December 31, 1996, bearing interest at
7-1/2% per annum. (See Note 13.) $ -- $281,004
Note payable - Carba, AG, due July 1, 1996,
requiring interest only payments at 6% per annum
with no current amortization required 293,426 293,426
Note payable - Carbamed-Ruegge Reduktion, due July 1, 1996,
requiring interest only payments at 6% per annum with no current
amortization required 130,605 130,605
Note payable - Dr. Zeman-Wiegand Helga, due on
demand, requires interest only payments at 7% per
annum with no current amortization required 87,070 87,070
-------- --------
511,101 792,105
Less: Current portion 511,101 87,070
-------- --------
$ -- $705,035
======== ========
</TABLE>
NOTE 17-COMMON STOCK
On June 6, 1994, the Company amended its certificate of incorporation to
change the number of authorized common shares from 50,000,000 to
15,000,000 of $.01 par value common stock.
The Company's outstanding shares of common stock of $.01 par value at
June 30, 1996 and 1995 were 14,185,064 and 12,035,064, respectively. The
shares include the retroactive effect given to the June 6, 1995 merger
between Swissray International, Inc. and SR Medical AG which was
recorded as a recapitalization of SR Medical AG.
NOTE 18-ISSUANCE OF COMMON STOCK FOR CASH
The Company issued 2,000,000 shares of common stock for $4,000,000
during the six month period ended June 30, 1995 and 2,150,000 shares for
$7,250,000 (includes 1,050,000 shares for $2,050,000 issued under stock
option plan) for the year ended June 30, 1996.
NOTE 19-PENSION PLAN
The Company, mandated by government regulations, is required to
contribute approximately five (5%) percent of eligible, as defined,
employees' salaries into a government pension plan. The Company also
contributes approximately five (5%) percent of eligible employee
salaries into a private pension plan. Total contributions charged to
operations for the year ended June 30, 1996, six months ended June 30,
1995, and year ended December 31, 1994 were $198,722, $96,718 and
$194,837, respectively.
F(11)
<PAGE> 35
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 20-OTHER INCOME (EXPENSES)
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------- ------------- ------------
<S> <C> <C> <C>
Licensing income $ 482,138 $ -- $ --
Interest income 131,166 -- --
Interest income - stockholder
and officer 12,530 4,376 5,744
Foreign currency income 377,587 16,158 10,948
Miscellaneous income 512 4,544 320
Loss from investments -- (16,909) (28,652)
Consulting fees - related party -- (3,050,000) --
Interest expense (193,930) (121,987) (237,013)
Miscellaneous expenses -- (11,826) (3,464)
--------- ----------- ---------
TOTAL OTHER INCOME (EXPENSES) $ 810,003 $(3,175,644) $(252,117)
========= =========== =========
</TABLE>
NOTE 21-INCOME TAXES
The Company adopted Statement of Financial Accounting Standard 109
("SFAS"). SFAS 109 provides for an asset and liability approach to
accounting for income taxes that require the recognition of deferred tax
assets and liabilities for the expected future tax consequences of
events that have been recognized in the Company's financial statements
or tax returns.
In estimating future consequences, SFAS 109 generally considers all
expected future events other than proposed changes in the tax law or
rates prior to enactment.
The provisions for deferred taxes for the year ended June 30, 1996, six
months ended June 30, 1995, and year ended December 31, 1994 were
$1,028,075, $367,900 and $-0-, respectively, as a result of foreign net
operating losses, and have been fully offset by a valuation allowance
for each period. The valuation allowances have been established equal to
the full amounts of the deferred tax assets, as the Company is not
assured that it more likely than not that these benefits will be
realized.
A reconciliation between the statutory federal income tax rate (34%) and
the effective income tax rates based on continuing operations is as
follows:
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------- ------------- ------------
<S> <C> <C> <C>
Statutory federal income tax (benefit) $(1,067,008) $(1,414,600) $ (58,600)
State income tax -- -- --
Foreign income tax (benefit) in
excess of domestic rate (325,715) (457,760) (18,973)
Benefit not recognized on operating loss -- 1,165,485 101,685
Valuation allowance 1,028,075 367,900 --
----------- ----------- ---------
$ (364,648) $ (338,975) $ 24,112
=========== =========== =========
</TABLE>
Foreign net operating loss carryforwards for the year ended June 30,
1996, six months ended June 30, 1995, and year ended December 31, 1994
were approximately $1,600,000, $3,400,000 and $-0-, respectively.
Foreign net operating losses carryforward indefinitely.
F(12)
<PAGE> 36
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 21-INCOME TAXES (CONTINUED)
The income tax related to the extraordinary gain on extinguishment of
debt was approximately $340,000 for the six months ended June 30, 1995.
The income tax related to the extraordinary gain on sale of marketable
securities was approximately $343,000 for the year ended June 30, 1996.
NOTE 22-EXTRAORDINARY GAINS
During 1995, the Company extinguished, at a discount, a $1,659,497 note
obligation. The transaction resulted in an extraordinary gain of
$415,695 ($.05 per share), net of income taxes of approximately
$340,000.
In June of 1996, the Company sold marketable securities for $962,500, at
a cost of $200,000, resulting in an extraordinary gain of $419,500 ($.03
per share), net of income taxes of approximately $343,000.
NOTE 23-SUPPLEMENTAL CASH FLOW INFORMATION
Cash payments for the year ended June 30, 1996, six months ended June
30, 1995, and year ended December 31, 1994 include interest of $193,930,
$121,987 and $237,013, respectively, and income taxes of $-0-, $1,025
and $24,112, respectively.
Non-cash operating activities consisted of issuance of common stock for
services for the six months ended June 30, 1995 in the amount of
$3,050,000.
Non-cash investing and finance activities for the six months ended June
30, 1995 consisted of the acquisition of a licensing agreement for
$4,966,575 for $885,571 in cash, a note obligation for $281,004, and the
issuance of common stock for $3,800,000. Total cash paid was $885,571.
For year ended June 30, 1996 the Company received a note receivable for
$962,500 from the sale of marketable securities. No cash was received.
NOTE 24-STOCK OPTIONS
The Board of Directors has adopted a non-statutory stock option plan and
reserved 3,000,000 shares for issuance to eligible full and part-time
employees, officers, directors and consultants. Options are
non-transferrable and are exercisable during a term of not more than ten
(10) years from the grant date. The options are issuable in such amounts
and at such prices as determined by the Board of Directors, except that
each option price of each grant will not be less than twenty (20%)
percent of the fair market value of such shares on the date the options
are granted.
The following table summarizes common stock options outstanding as of
June 30, 1996.
<TABLE>
<CAPTION>
Price Per Options Options Options
Date Granted Share Granted Exercised Outstanding
------------ --------- --------- --------- -----------
<S> <C> <C> <C> <C>
September 20, 1995 $6.50 200,000 -- 200,000
June 8, 1996 5.00 100,000 -- 100,000
March 11, 1996 2.00 2,000,000 1,000,000 1,000,000
May 16, 1996 4.75 35,000 -- 35,000
--------- --------- ---------
2,335,000 1,000,000 1,335,000
========= ========= =========
</TABLE>
On July 22, 1996, the Company granted 200,000 shares of the Company's
common stock under the 1996 non-statutory stock option plan with an
exercise price of $.73 per share.
F(13)
<PAGE> 37
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 25-SIGNIFICANT CUSTOMER AND GEOGRAPHIC AREAS
The Company presently has no domestic operations and derives all of its'
revenues from its subsidiaries located in Switzerland and Germany.
Domestic (Switzerland and Germany) and export sales were as follows:
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------- ------------- ------------
<S> <C> <C> <C>
Switzerland $ 2,002,374 $1,980,606 $1,165,730
Germany 4,976,503 1,029,413 2,334,265
Other export sales 3,920,345 796,294 5,117,609
----------- ---------- ----------
$10,899,222 $3,806,313 $8,617,604
=========== ========== ==========
</TABLE>
The following summarizes customers sales in excess of 10% or more of the
total revenues:
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------- ------------- ------------
<S> <C> <C> <C>
Three largest customers:
Sales $4,499,893 $1,938,937 $4,894,201
Percentage 41% 51% 57%
Single largest customer:
Sales $1,603,631 $1,431,705 $3,232,206
Percentage 15% 38% 38%
</TABLE>
The accounts receivable balance at June 30, 1996 from the three largest
customers amounted to approximately $1,650,000 representing approximately 48% of
total trade accounts receivable with the single largest customer balance of
approximately $1,500,000 representing approximately 44% of total trade
receivables. The accounts receivable balance at June 30, 1995 from the three
largest customers amounted to approximately $1,200,000 representing
approximately 44% of total trade accounts receivable with the single largest
customer balance of approximately $900,000 representing approximately 34% of
total trade accounts receivable.
The following summarizes operating profit (losses) before provision for
income tax by geographic areas:
<TABLE>
<CAPTION>
Six Months Year Ended
Year Ended Ended December 31,
June 30, 1996 June 30, 1995 1994
------------- ------------- ------------
<S> <C> <C> <C>
Switzerland $(2,312,087) $(4,095,783) $(295,805)
Germany (63,673) (65,032) 123,325
----------- ----------- ---------
$(2,375,760) $(4,160,815) $(172,480)
=========== =========== =========
</TABLE>
The following summarizes identifiable assets by geographic area:
<TABLE>
<CAPTION>
June 30,
--------------------------
1996 1995
----------- -----------
<S> <C> <C>
Switzerland $18,369,530 $12,513,262
Germany 664,076 514,094
----------- -----------
$19,033,606 $13,027,356
=========== ===========
</TABLE>
F(14)
<PAGE> 38
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996 AND 1995 AND DECEMBER 31, 1994
NOTE 26-COMMITMENTS
The Company leases various facilities and vehicles under operating lease
agreements expiring through September 2002. The Company has excluded all
vehicle leases in the schedule below because they are deemed to be
immaterial. The facilities lease agreements provide for a base monthly
payment of $15,884 per month. Rent expense for the year ended June 30,
1996, six months ended June 30, 1995, and year ended December 31, 1994
were $242,658, $148,818 and $185,459, respectively.
Future minimum annual lease payments, based on the exchange rate in
effect on June 30, 1996, under the facilities lease agreements are as
follows:
<TABLE>
<CAPTION>
Year Ended
June 30,
----------
<S> <C>
1997 $190,611
1998 190,611
1999 178,759
2000 143,204
2001 129,065
Thereafter 143,658
</TABLE>
NOTE 27-LITIGATION
On or about July 7, 1995, the Company commenced litigation against a
former officer and director of a corporate predecessor alleging certain
improprieties on the part of such officer and seeking monetary
compensation as a result thereof. Such defendant responded (in September
1995) by filing certain affirmative defenses and counterclaims against
the Company and others and subsequently brought (together with certain
of his family members) an action against the Company in the same court
which action raised issues and claims substantially similar to those
raised in the aforesaid counterclaims. The two actions were assigned to
the same judge and the Company moved successfully to dismiss both the
counterclaims and the second action. Leave to replead both claims were
granted and amended counterclaims and an amended complaint were served
and filed and the Company again successfully moved to dismiss both
pleadings. Following the most recent dismissal, counsel for the Company
and the aforesaid former officer entered into settlement discussions
which continue to date and to date no new pleadings have been served.
Owing to the above set of facts regarding the current status of the
litigation and further owing to the fact that discovery proceedings have
not even been scheduled as yet, it is virtually impossible to determine,
with any degree of certainty, the final outcome of this litigation
although the Company fully expects to prevail on all material aspects of
this law suit.
NOTE 28-RELATED PARTY TRANSACTIONS
The Company entered into agreements with Berkshire Capital Management
Ltd., (Berkshire), a stockholder, whereby Berkshire would render
consulting and related services towards and in regards with the
acquisition of SR Medical AG and subsidiaries. Berkshire received
1,525,000 shares of the Company's restricted common stock in full
payment of service rendered in June of 1995 which were valued at
$3,050,000 ($2 per share).
F(15)
<PAGE> 39
ITEM 8. CHANGES IN THE AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
No disagreements with accountants on accounting and financial disclosure
matters existed during the Company's fiscal year ended June 30, 1996.
PART III
ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT
The Directors and Executive Officers of the Company, as of October 1,
1996, were as follows:
Name Position(s) Held Age
- ---- ---------------- ---
Ruedi G. Laupper President and Director 46
Josef Laupper Secretary and a 51
Director
Ulrich Ernst Treasurer and Chairman 49
of the Board of Directors
Dr. Erwin Zimmereli Director 49
Directors are elected to serve until the next annual meeting of
stockholders and until their successors have been elected and have qualified.
Officers are appointed to serve until the meeting of the Board of Directors
following the next annual meeting of stockholders and until their successors
have been elected and have qualified.
RUEDI G. LAUPPER has been President and a director of the Company since
May, 1995 and has been President and a director of both SR-Medical AG and
Teleray AG since their respective incorporations in 1988 and 1984 respectively.
Additionally, Ruedi G. Laupper has served as President of SR Finance AG, a
wholly owned subsidiary of the Company, since its incorporation in December
1995. He has approximately 16 years of experience in the field of radiology and
direct market knowledge as well as important business contacts throughout the
industry and with key clientele.
JOSEF LAUPPER is the brother of the Company's President and has been
Secretary and a director of the Company since May, 1995 maintaining comparable
positions with both SR- Medical AG and Teleray AG since their respective dates
of incorporation. Josef Laupper also serves as Managing Director of SR Finance
AG since its inception in December 1995. He is
24
<PAGE> 40
principally in charge of the Company's financial, logistical and administrative
tasks. As a former entrepreneur in the medical supply business, Josef Laupper
has in excess of 17 years of financial and marketing experience within the
industry.
ULRICH ERNST has been Chairman of the Board of Directors and Treasurer of
the Company since May, 1995 and has had approximately 24 years of experience in
international business development in various industries with background
primarily in management consulting, financial advisory services and rendering
advice to new growth business ventures. Mr. Ernst received his Diploma in
Economic Studies in 1968 from the School of Economics and received his Masters
of Business Administration degree in 1973 from the University of Zurich.
DR. ERWIN ZIMMERLI has been a director of the Company since May, 1995.
Since receiving his Graduate in law and economics degree from the University of
St. Gall, Switzerland (PhD) in 1979, Dr. Zimmerli has served as (a) head of the
White Collar Crime Department of the Zurich State Police (1980-86), (b) an
expert of a Parliamentary Commission for penal law and Lecturer at the
Universities of St. Gall and Zurich (1980-87), (c) Vice President of a leading
auditing firm (1987-1990) and (d) Executive Vice President of a multinational
aviation company (1990-92). Since 1992 he has been actively engaged in various
independent consulting capacities primarily within the legal community.
Additional Key Personnel
UELI LAUPPER, 26 years of age, is the son of the Company's President with
overall Company responsibilities in the area of Marketing and Sales with
approximately two years of experience within the international X-ray market.
DR. MARKUS MEIER, 43 years of age, has been manager of the Company's
Research and Development division since October 1996. Dr. Meier has a degree in
physics, had been Project Manager at Asea Brown Boveri ("ABB") and Professor at
Technical University in Switzerland with extensive experience in the field of
Optics and Bulk Optics.
GERARDUS PETERS, 52 years of age, jointed SR-Medical AG in 1994 after
leaving Landis & Gyr. He has been a production professional for over 25 years
and his primary responsibilities lie in the area of establishing a quality
assurance system for the Company.
ALOIS SUPPIGER, 39 years of age, has been employed for over 10 years by
the Company's subsidiary, being in charge of technical support within the
Company's subsidiaries distribution and sales network and also coordinates
product development with outsourcing partners.
25
<PAGE> 41
ITEM 10. EXECUTIVE COMPENSATION
Remuneration paid (and/or accrued, if applicable and so specifically
indicated) to current officers and/or directors of the Company during fiscal
year ended June 30, 1996 is indicated in the chart appearing directly
hereinafter.
<TABLE>
<CAPTION>
Securities
Salaries, Fees, or Property, Aggregate of
Capacities Directors' Fees, Insurance Benefits Contingent
Name of In Which Commissions or Reimbursement, Forms of
Individual Served and Bonuses Personal Benefits (3) Remuneration
- ---------- ---------- ---------------- --------------------- ------------
<S> <C> <C> <C> <C>
Ruedi Laupper President and a $176,085(1) -0- -0-
Director
Josef Laupper Secretary and a $118,229 -0- -0-
Director
Ulrich Ernst Treasurer and $113,197 -0- -0-
Chairman of the
Board Directors
Erwin Zimmereli Director $ 8,385 -0- -0-
Peter Wagli Former Officer of $123,763 -0- -0-
Telray AG (1)
Ueli Laupper (2) $ 73,117 -0- -0-
</TABLE>
(1) Mr. Wagli was neither an officer or director of the Company but was an
officer of Telray AG, a wholly owned subsidiary of SR-Medical AG, with the
latter being a wholly owned subsidiary of the Company. He no longer serves
in such capacity.
(2) Mr. Ueli Laupper is a key employee of the Company. See Additional Key
Personnel. His primarily activities relate to services rendered directly
to SR Medical AG, a wholly owned subsidiary of the Company.
(3) See also note 18 to consolidated financial statements with respect to
Swiss Mandated Pension Plan whereby the Company is required to contribute
approximately 5% of eligible employees salaries into a government pension
plan and the fact that the Company additionally contributes approximately
5% of eligible employees salaries into a private pension plan with total
contributions charged to operations. Total contributions for fiscal year
ended June 30, 1996 amounted to $198,722.
There are no current written employment agreements between the Company and
any of its officers and directors.
26
<PAGE> 42
No compensation of any nature was paid to any director for services
rendered to the Company in such capacity excepting as indicated herein or for
repayment made, if any, for accountable expenses incurred on the Company's
behalf.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
(a) Security Ownership of Certain Beneficial Owners - The following
persons and/or firms are known to the Company to be the beneficial owners of
more than 5% of the 13,751,142 shares of the Company's outstanding $.01 par
value Common Stock as of October 2, 1996. To the best of the Company's knowledge
each individual and/or firm has beneficial ownership of the shares and each
individual and/or firm has sole voting power and sole investment power with
respect to the number of shares beneficially owned.
<TABLE>
<CAPTION>
Name and Address of Amount and Nature of Percent
Beneficial Owner Beneficial Ownership of Class
- ------------------- -------------------- --------
<S> <C> <C>
Tomlinson Holding Inc.(1) 3,200,000 23.27%
Postfach 925
6301 Zug
Switzerland
</TABLE>
(1) These shares are indicated in Item (b) hereof as being beneficially owned
by the Company's President, Ruedi G. Laupper.
(b) Security Ownership of Management - The number and percentage of shares
of $.01 par value Common Stock of the Company owned of record and beneficially,
by each current officer and director of the Company and by all current officers
and directors of the Company as a group, is as follows - as of October 2, 1996.
To the best of the Company's knowledge each individual has beneficial ownership
of the shares and each individual has sole voting power and sole investment
power with respect to the number of shares beneficially owned.
<TABLE>
<CAPTION>
Name and Address of Amount and Nature of Percent
Beneficial Owner Beneficial Ownership of Class
- ------------------- -------------------- --------
<S> <C> <C>
Ruedi G. Laupper 3,200,000(1) 23.27%
c/o SWISSRAY International, Inc.
Industriestrasse 6
CH 6285 Hitzkirch
Switzerland
Josef Laupper 500,000(1) 3.64%
c/o SWISSRAY International, Inc.
Industriestrasse 6
CH 6285 Hitzkirch
Switzerland
</TABLE>
(1) The number of shares indicated alongside these individuals names include
all shares owned by corporations over which they exercise control by
virtue of stock ownership and/or positions held therein .
27
<PAGE> 43
<TABLE>
<CAPTION>
Name and Address of Amount and Nature of Percent
Beneficial Owner Beneficial Ownership of Class
- ------------------- -------------------- --------
<S> <C> <C>
Ulrich Ernst 70,000(1) .51%
c/o SWISSRAY International, Inc.
Industriestrasse 6
CH 6285 Hitzkirch
Switzerland
Dr. Erwin Zimmereli -0- -0-
c/o SWISSRAY International, Inc.
Industriestrasse 6
CH 6285 Hitzkirch
Switzerland
</TABLE>
(1) The number of shares indicated alongside these individuals names include
all shares owned by corporations over which they exercise control by
virtue of stock ownership and/or positions held therein .
The Company does not know of any arrangement or pledge of its securities
by persons now considered in control of the Company that might result in a
change of control.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
For the fiscal year ended June 30, 1996 there have not been any material
transactions between the Company and any director, executive officer, security
holder or any member of the immediate family of any of the aforementioned which
exceeded $60,000 other than as may be indicated in this Form 10-KSB and the
audited consolidated financial statements and notes thereto which are a part
hereof.
ITEM 13. EXHIBITS, LIST AND REPORTS ON FORM 8-K
Reference is herewith made to pages F-1 through F-15 inclusive of this
10-KSB with respect to the financial statements and notes thereto included
therein.
No exhibits are being filed with this Form 10-KSB.
During the last quarter of the Company's fiscal year ended June 30, 1996
no Form 8-K was filed. However, during the first quarter of fiscal year ended
June 30, 1997 the Company filed a Form 8-K with the Securities and Exchange
Commission on July 3, 1996 with date of report of July 1, 1996, which Form 8-K
indicated (at Item 5 - Other Events thereto) that the Company had issued a press
release dated July 1, 1996 (which press release was annexed as an exhibit to
such Form 8-K).
28
<PAGE> 44
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
SWISSRAY International, Inc.
By /Ruedi Laupper/
----------------------------
Ruedi Laupper, President
Date: October 10, 1996
In accordance with the Exchange act, This report has been signed below by
the following persons on behalf of the registrant and in the capacities and on
the dates indicated.
/Ruedi Laupper/ President and Dated: Oct. 10, 1996
- ---------------------------- a Director
Ruedi Laupper
/Josef Laupper/ Secretary-Treasurer Dated: Oct. 10, 1996
- ---------------------------- and a Director
Josef Laupper
/Ulrich Ernst/ Chairman of the Dated: Oct. 10, 1996
- ---------------------------- Board of Directors
Ulrich Ernst
- ---------------------------- Director Dated: Oct. , 1996
Dr. Erwin Zimmereli
29
<PAGE> 45
SUPPLEMENTAL INFORMATION
Supplemental Information to be Furnished With Reports Filed Pursuant to
Section 15(d) of the Act by Registrants Which Have Not Registered Securities
Pursuant to Section 12 of the Act.
The Company's fiscal year ended June 30, 1996. While the Company does
currently intend to hold an annual meeting of stockholders for its fiscal year
ended June 30, 1996 prior to the close of the current calendar year but has not,
as yet, formalized any specific plans as to any proposed date or site (within or
without the U.S.) for such meeting.
Four copies of all material to be mailed to stockholders with respect to
such Annual Meeting of Stockholders (when scheduled to be held) will be
furnished to the Securities and Exchange Commission but such documents, when
furnished, will not be deemed to be "filed" with the Securities and Exchange
Commission or otherwise subject to liabilities of Section 18 of the Act (except
to the extent that the Registrant specifically incorporates such material by
reference in any subsequent Form 10-KSB); it is expected that such documents
will consist of a Form of Proxy, Notice of Annual Meeting with Information
Statement as well as such schedules and/or exhibits as may be annexed thereto.
30
<PAGE> 46
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
27 FINANCIAL DATA SCHEDULE
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM BALANCE
SHEET, STATEMENT OF OPERATIONS, AND STATEMENT OF STOCKHOLDERS EQUITY AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10K-SB.
</LEGEND>
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> JUN-30-1996
<PERIOD-START> JUL-01-1995
<PERIOD-END> JUN-30-1996
<CASH> 3,252,685
<SECURITIES> 0
<RECEIVABLES> 3,225,836
<ALLOWANCES> 109,843
<INVENTORY> 2,912,836
<CURRENT-ASSETS> 11,570,914
<PP&E> 1,372,277
<DEPRECIATION> 233,995
<TOTAL-ASSETS> 18,733,438
<CURRENT-LIABILITIES> 8,138,182
<BONDS> 0
0
0
<COMMON> 141,851
<OTHER-SE> 10,513,405
<TOTAL-LIABILITY-AND-EQUITY> 18,793,438
<SALES> 10,899,222
<TOTAL-REVENUES> 10,899,222
<CGS> 5,793,306
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 8,591,679
<LOSS-PROVISION> 491,487
<INTEREST-EXPENSE> 193,930
<INCOME-PRETAX> (2,675,760)
<INCOME-TAX> (364,648)
<INCOME-CONTINUING> (2,311,112)
<DISCONTINUED> 0
<EXTRAORDINARY> 19,500
<CHANGES> 0
<NET-INCOME> (1,891,612)
<EPS-PRIMARY> (.15)
<EPS-DILUTED> (.15)
</TABLE>
